Why Roche Holding Stock Popped Today
Roche Holding (OTC: RHHBY) stock jumped 3.4% through 1:05 p.m. ET Monday after the pharmaceutical giant's Genentech subsidiary announced positive phase 3 clinical trial results for its fenebrutinib drug for treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Image source: Getty Images.
Conducted over more than 96 weeks, the first trial "significantly reduced the annualized relapse rate (ARR) compared to teriflunomide," an RMS drug developed by Sanofi and currently available as a generic from multiple manufacturers.
Source Fool.com
Roche Holding AG ADR Aktie
42,30 €
-1,23 %
Die Community bevorzugt leicht Roche Holding AG ADR mit mehr Buy- als Sell-Einschätzungen.
Das von der Community festgelegte Kursziel von 46 € für Roche Holding AG ADR deutet auf ein leichtes Wachstumspotenzial im Vergleich zu 42.3 € hin.
